Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Status:
NOT_YET_RECRUITING
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL).
The names of the study drugs involved in this study are:
* Venetoclax (a type of inhibitor)
* Rituximab (a type of antibody)